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The unprecedented growth of new psychoactive substances (NPS) render identification a 
challenging issue to both the forensic and clinical laboratories. NPS readily available in 
myriad of unknown formulation, posing serious threat and acute harm for the users. At 
present, there is paucity of information on the potential potency, toxicity mechanisms, 
and toxicokinetic parameters associated with the use of these drugs. The present study 
aimed to investigate the neurotoxicity potency and cellular mechanism of NPS. 
Hepatoxicity potency potential, metabolic stability and subsequent metabolism pathway 
of specific NPS is also explored for better understanding of the toxicokinetics of these 
NPS.   
 
The neurotoxicity potential and mechanism of synthetic cathinones (SCs) 
butylone, pentylone and 3,4-methylenedioxypyrovalerone (MDPV) was investigated 
using differentiated SH-SY5Y cell line. Viability assays and end-point measurements that 
include markers of oxidative stress, mitochondrial bioenergetics, intracellular calcium 
(Ca2+) and cell death pathways were employed. All the three SCs displayed dose-
dependent neurotoxicity with the following order of potency: butylone (least cytotoxic) 
< pentylone < MDPV (most cytotoxic). The activation of apoptotic cell death pathway 
implicated the orchestration of mitochondrial-mediated neurotoxicity mechanisms via 
oxidative stress, compromised bioenergetics balance and changes in Ca2+ homeostasis (p 
< 0.0001 vs. control).  
 
The metabolism of synthetic cannabinoid (SCB), 4F-MDMB-BINACA was 
investigated using in vitro models: HepG2 liver cells, fungus Cunninghamella elegans 
(C. elegans) and pooled human liver microsomes (HLM). Tentative structure elucidation 
of the in vitro metabolites was performed using high-resolution mass spectrometry whilst 
twenty authentic human urine samples were retrospectively analysed using liquid 
chromatography-orbitrap mass spectrometry. A total of twenty-five in vitro metabolites 
and eight in vivo metabolites were tentatively identified. Ester hydrolysis and ester 
hydrolysis dehydrogenation 4F-MDMB-BINACA metabolites were recommended as 
urinary markers for 4F-MDMB-BINACA intake. C. elegans has the potential to be used 
xi 
 
as a complementary model to predict and characterise human metabolites, as well as 
identifying possible drug toxicities for emerging SCBs.  
 
The metabolic stability and hepatotoxicity potential of butylone, pentylone, 
MDPV and 4F-MDMB-BINACA were studied using HLM and HepG2 liver cells, 
respectively. Drug-treated HepG2 exhibited the following cytotoxicity potency: butylone 
(least cytotoxic) < pentylone < MDPV < 4F-MDMB-BINACA (most cytotoxic). For the 
metabolic stability study, NPS incubated in HLM were collected at various time points 
and subsequently analysed by liquid-chromatography tandem mass spectrometry. 
Calculated in vitro half‐lives together with estimated intrinsic clearance values 
categorised butylone, pentylone and MPDV as low clearance drugs and 4F-MDMB-
BINACA as high clearance drug.  
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